| Dr Mehrdad Saririan, MD | |
|
2601 E. Roosevelt Street, Phoenix, AZ 85008 | |
| (602) 344-5188 | |
| (602) 344-1233 |
| Full Name | Dr Mehrdad Saririan |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 27 Years |
| Location | 2601 E. Roosevelt Street, Phoenix, Arizona |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083669998 | NPI | - | NPPES |
| 958134 | Medicaid | AZ |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 34229 (Arizona) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Valleywise Health Medical Center | Phoenix, AZ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| District Medical Group Inc | 7315086691 | 356 |
News Archive
Over 90 per cent of physicians treating actinic keratosis (AK) prefer short duration treatment options with fast resolving local skin responses (LSRs), is the finding of a global study (‘Physician Perceptions and Experience of Current Treatment in Actinic Keratosis') that is being presented today at the 22nd Congress of the European Academy of Dermatology and Venereology (EADV).
The National Institute of Mental Health has awarded the CUNY Graduate School of Public Health and Health Policy and the New York City Department of Health and Mental Hygiene a five-year, $3.3 million grant to test a new strategy to help people living with HIV achieve viral suppression.
Boston Medical Center's Grayken Center for Addiction has received a five-year, $3.7 million grant from the Health Resources and Services Administration to expand its fellowship programs in addiction medicine and addiction psychiatry.
Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported that enrollment has begun for a pilot study to assess the safety and efficacy of Iluvien(R) in patients with macular edema secondary to retinal vein occlusion.
› Verified 4 days ago
| Entity Name | Maricopa County Special Health Care District |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073576740 PECOS PAC ID: 4688583651 Enrollment ID: O20031204000823 |
News Archive
Over 90 per cent of physicians treating actinic keratosis (AK) prefer short duration treatment options with fast resolving local skin responses (LSRs), is the finding of a global study (‘Physician Perceptions and Experience of Current Treatment in Actinic Keratosis') that is being presented today at the 22nd Congress of the European Academy of Dermatology and Venereology (EADV).
The National Institute of Mental Health has awarded the CUNY Graduate School of Public Health and Health Policy and the New York City Department of Health and Mental Hygiene a five-year, $3.3 million grant to test a new strategy to help people living with HIV achieve viral suppression.
Boston Medical Center's Grayken Center for Addiction has received a five-year, $3.7 million grant from the Health Resources and Services Administration to expand its fellowship programs in addiction medicine and addiction psychiatry.
Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported that enrollment has begun for a pilot study to assess the safety and efficacy of Iluvien(R) in patients with macular edema secondary to retinal vein occlusion.
› Verified 4 days ago
| Entity Name | Jewish Family & Childrens Service |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023174455 PECOS PAC ID: 9234028671 Enrollment ID: O20040312001009 |
News Archive
Over 90 per cent of physicians treating actinic keratosis (AK) prefer short duration treatment options with fast resolving local skin responses (LSRs), is the finding of a global study (‘Physician Perceptions and Experience of Current Treatment in Actinic Keratosis') that is being presented today at the 22nd Congress of the European Academy of Dermatology and Venereology (EADV).
The National Institute of Mental Health has awarded the CUNY Graduate School of Public Health and Health Policy and the New York City Department of Health and Mental Hygiene a five-year, $3.3 million grant to test a new strategy to help people living with HIV achieve viral suppression.
Boston Medical Center's Grayken Center for Addiction has received a five-year, $3.7 million grant from the Health Resources and Services Administration to expand its fellowship programs in addiction medicine and addiction psychiatry.
Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported that enrollment has begun for a pilot study to assess the safety and efficacy of Iluvien(R) in patients with macular edema secondary to retinal vein occlusion.
› Verified 4 days ago
| Entity Name | District Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1336472448 PECOS PAC ID: 7315086691 Enrollment ID: O20091125000583 |
News Archive
Over 90 per cent of physicians treating actinic keratosis (AK) prefer short duration treatment options with fast resolving local skin responses (LSRs), is the finding of a global study (‘Physician Perceptions and Experience of Current Treatment in Actinic Keratosis') that is being presented today at the 22nd Congress of the European Academy of Dermatology and Venereology (EADV).
The National Institute of Mental Health has awarded the CUNY Graduate School of Public Health and Health Policy and the New York City Department of Health and Mental Hygiene a five-year, $3.3 million grant to test a new strategy to help people living with HIV achieve viral suppression.
Boston Medical Center's Grayken Center for Addiction has received a five-year, $3.7 million grant from the Health Resources and Services Administration to expand its fellowship programs in addiction medicine and addiction psychiatry.
Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported that enrollment has begun for a pilot study to assess the safety and efficacy of Iluvien(R) in patients with macular edema secondary to retinal vein occlusion.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mehrdad Saririan, MD 2929 E. Thomas Road, Phoenix, AZ 85016 Ph: (602) 470-5000 | Dr Mehrdad Saririan, MD 2601 E. Roosevelt Street, Phoenix, AZ 85008 Ph: (602) 344-5188 |
News Archive
Over 90 per cent of physicians treating actinic keratosis (AK) prefer short duration treatment options with fast resolving local skin responses (LSRs), is the finding of a global study (‘Physician Perceptions and Experience of Current Treatment in Actinic Keratosis') that is being presented today at the 22nd Congress of the European Academy of Dermatology and Venereology (EADV).
The National Institute of Mental Health has awarded the CUNY Graduate School of Public Health and Health Policy and the New York City Department of Health and Mental Hygiene a five-year, $3.3 million grant to test a new strategy to help people living with HIV achieve viral suppression.
Boston Medical Center's Grayken Center for Addiction has received a five-year, $3.7 million grant from the Health Resources and Services Administration to expand its fellowship programs in addiction medicine and addiction psychiatry.
Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported that enrollment has begun for a pilot study to assess the safety and efficacy of Iluvien(R) in patients with macular edema secondary to retinal vein occlusion.
› Verified 4 days ago
Moustafa I Hazin, D.O. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 500 W Thomas Rd, Suite 900, Phoenix, AZ 85013 Phone: 602-406-5590 Fax: 602-406-7165 | |
Dr. Ali Shaheen Al-yaqoobi, M.D. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 2601 E Roosevelt St, Phoenix, AZ 85008 Phone: 602-344-5411 | |
Dana Archbold, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 1111 E Mcdowell Rd, Phoenix, AZ 85006 Phone: 602-839-2296 Fax: 602-839-2084 | |
Catalina Nicole Flores, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 350 W Thomas Rd Dept Of, Phoenix, AZ 85013 Phone: 602-406-3000 | |
Kristina Yancey, Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 5777 E Mayo Blvd, Phoenix, AZ 85054 Phone: 480-342-2000 | |
Dr. Francisco Cordova, MD Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 29 W Edgemont Ave, Phoenix, AZ 85003 Phone: 602-263-8971 Fax: 602-263-8971 | |
Dr. Dimpy Kapoor, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 9305 W Thomas Rd, Ste 455, Phoenix, AZ 85037 Phone: 623-399-9010 Fax: 623-399-9013 |